Review
Endocrinology & Metabolism
Svetlana Lebedeva, Arus Margaryan, Elena Smolyarchuk, Andrey Nedorubov, Maria Materenchuk, Alexander Tonevitsky, Kerim Mutig
Summary: Diabetic kidney disease is the major cause of chronic kidney disease, and enhanced plasma vasopressin levels have been associated with it. Vasopressin has diuretic effects in the kidneys and adaptive effects in other organs. Overactivation of certain vasopressin receptors can lead to kidney problems and worsen diabetic kidney disease.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Ignazio Verzicco, Stefano Tedeschi, Gallia Graiani, Alice Bongrani, Maria Luisa Carnevali, Simona Dancelli, Jessica Zappa, Silvia Mattei, Achiropita Bovino, Stefania Cavazzini, Rossana Rocco, Anna Calvi, Barbara Palladini, Riccardo Volpi, Valentina Cannone, Pietro Coghi, Alberico Borghetti, Aderville Cabassi
Summary: This study found an increased sensitivity to ADH in young female SHR, which promotes the development of hypertension. Early treatment with selective V2 antagonists can delay the future development of hypertension in SHR.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Michael Horckmans, Esteban Diaz Villamil, Celine Verdier, Henrik Laurell, Jean-Bernard Ruidavets, Lucas De Roeck, Guillaume Combes, Laurent O. O. Martinez, Didier Communi
Summary: Loss-of-function mutation of the human P2Y(4) receptor is associated with less severe coronary artery atherosclerosis and lower fasting plasma glucose in coronary patients. Mouse experiments confirmed the role of the P2Y(4) receptor in glucose homeostasis. P2Y(4) antagonists could potentially be used in the treatment of myocardial infarction and type 2 diabetes.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Randi J. Ulbricht, Christian A. Rivas, Hailee Marino, Erin Snyder, Dana James, Jamila Makhloufi, Nathan Johnson, Scott Zimmerman, Jianjie Wang
Summary: The sex of an animal impacts glucose sensitivity, and the P2Y2 receptor (P2Y2R) plays a larger role in male mice during acute inflammation. Female mice have reduced fasting plasma glucose levels and better glucose tolerance compared to males. P2Y2R has minimal effect on glucose metabolism in females but is significant in males, particularly in an inflamed state.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Multidisciplinary Sciences
Maysam Mansouri, Marie-Didiee Hussherr, Tobias Strittmatter, Peter Buchmann, Shuai Xue, Gieri Camenisch, Martin Fussenegger
Summary: The study introduces a wearable smart electronic device-controlled gene switch for treating diabetes, utilizing green-light operation. By remotely controlling implanted engineered human cells, the switch can release human glucagon-like peptide-1 as needed, effectively treating diabetes. Interfacing wearable smart devices with therapeutic gene expression may advance personalized therapies by connecting biopharmaceutical interventions to the internet of things.
NATURE COMMUNICATIONS
(2021)
Article
Endocrinology & Metabolism
Jinbo Huang, Shuai Xue, Peter Buchmann, Ana Palma Teixeira, Martin Fussenegger
Summary: Huang et al. have developed an electrogenetic interface called DART, which allows electrode-mediated stimulation of gene expression in human cells using direct current. In a mouse model of type 1 diabetes, this interface was able to stimulate insulin expression and alleviate hyperglycemia. This technology provides a missing link for wearable electronic devices to directly program gene-based therapies.
Review
Endocrinology & Metabolism
Xiaohui Pan, Shibing Tao, Nanwei Tong
Summary: Neurotransmitters play a vital role in regulating glucose homeostasis in pancreatic islets, and dysfunction of neurotransmitter receptors is associated with the development of type 2 diabetes. Targeting different transmitter systems holds great potential in preventing and treating type 2 diabetes and other metabolic diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Multidisciplinary Sciences
Shruti Mohan, Ryan Lafferty, Neil Tanday, Peter R. Flatt, R. Charlotte Moffett, Nigel Irwin
Summary: The study demonstrated that sustained treatment of Ac3IV has a positive impact on pancreatic islet cell morphology and transdifferentiation in diabetic mice, increasing insulin levels and reversing detrimental effects. Ac3IV also promoted beta-cell proliferation, decreased apoptosis, and partially reversed beta- to alpha-cell differentiation. Additionally, it improved islet architecture, with increased transition of alpha- to beta-cells and increased CK-19 co-expression with insulin in pancreatic ductal and islet cells.
Article
Endocrinology & Metabolism
Yijun Lin, Meijuan Bai, Shuo Wang, Lingling Chen, Zixuan Li, Chenchen Li, Peijuan Cao, Yan Chen
Summary: This study identifies lactate as a key trigger for obesity-induced inflammation and systemic insulin resistance. Accumulation of lactate in adipocytes leads to apoptosis and release of cytokines, which initiates inflammation and insulin resistance.
Article
Cell Biology
Tomoki Yagai, Tingting Yan, Yuhong Luo, Shogo Takahashi, Daisuke Aibara, Donghwan Kim, Chad N. Brocker, Moshe Levi, Hozumi Motohashi, Frank J. Gonzalez
Summary: This study reveals the regulatory axis of let-7-RNF8-RXRα in modulating hepatic lipid catabolism.
Article
Pharmacology & Pharmacy
Priscila L. Zimath, Milena S. Almeida, Maciel A. Bruxel, Alex Rafacho
Summary: In this study, the potential therapeutic application of mometasone furoate (MF) with fewer adverse effects was investigated. It was found that MF maintained anti-inflammatory activity, but intraperitoneal administration led to glucose intolerance, while oral administration did not. Regardless of the route of administration, MF reduced insulin sensitivity and increased pancreatic beta-cell mass. Overall, oral administration of MF minimized the adverse effects on metabolism.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Huiling Hu, Nannan Sun, Haiyan Du, Yuqing He, Kunyi Pan, Xiuli Liu, Xiaoxia Lu, Jie Wei, Mianmian Liao, Chaohui Duan
Summary: Previous studies have shown that PLZF plays a role in promoting gluconeogenic gene expression, hepatic glucose output, and consequent hyperglycemia. However, its role in regulating lipid metabolism was unknown. This study revealed that PLZF is an essential regulator of hepatic lipid and glucose metabolism. Overexpression of PLZF in the liver led to fatty liver, inflammation, impaired glucose tolerance, and insulin sensitivity. Knockdown of PLZF in obese mice alleviated hepatic steatosis. The underlying mechanism involved PLZF activating SREBP-1c gene transcription by binding to its promoter fragment, which depended on its interaction with SIRT1 to induce a repressor-to-activator conversion. These findings suggest that modulating PLZF expression in the liver could be a potential therapeutic approach for treating NAFLD.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Aleksandra Sedzikowska, Leszek Szablewski
Summary: The kidney plays a crucial role in glucose homeostasis by releasing glucose into the blood stream using carrier proteins for transport. Mutations in genes encoding glucose transporters can lead to renal disorders, impacting glucose transport and renal function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
Clara Odilia Sailer, Odile Gaisl, Svetlana Beglinger, Martina Frech-Dorfler, Vivienne Sommer, Maya Horst Luthy, Mirjam Christ-Crain
Summary: This study found that plasma copeptin ratio can predict the treatment response to desmopressin in children with monosymptomatic nocturnal enuresis. A lower copeptin ratio indicates a better treatment response to desmopressin.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Medicine, Research & Experimental
Byungtae Hwang, Min-Gi Kwon, Min Ji Cho, Nam-Kyung Lee, Jangwook Lee, Jeong Woong Lee, Kyoung-Jin Oh, Kwang-Hee Bae, Jung Hwan Hwang, Jeong-Ki Min, Jong-Gil Park
Summary: This study highlights the critical role of PTP4A1 in regulating hepatosteatosis and glucose homeostasis. It demonstrates that PTP4A1 prevents the accumulation of hepatic lipids and regulates glucose uptake by activating the CREBH/FGF21 axis. Modulating PTP4A1 may offer a potential therapeutic strategy against hepatosteatosis-related diseases.